USP Medicare Formulary Classes Should Use Mechanism Of Action, PhRMA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Subclasses should be based on other clinically relevant pharmacological characteristics, PhRMA tells USP pharmaceutical manufacturers forum. There should be enough classes to include the top 200 drugs for each of three Medicare subpopulations, PhRMA says.
You may also be interested in...
Drug Choice Particularly Important In Medicare Population – PhRMA Study
A PhRMA-sponsored study of ACE inhibitor, SSRI and insulin labels examined differences within the classes, including indication, route of elimination and interactions. Drug variations and characteristics of the elderly population make flexibility particularly important when designing formularies for the Medicare drug benefit, the study concludes.
Drug Choice Particularly Important In Medicare Population – PhRMA Study
A PhRMA-sponsored study of ACE inhibitor, SSRI and insulin labels examined differences within the classes, including indication, route of elimination and interactions. Drug variations and characteristics of the elderly population make flexibility particularly important when designing formularies for the Medicare drug benefit, the study concludes.
USP Draft Medicare Formulary Sets 146 Drug Categories And Classes
The proposed total is greater than the number of classes desired by PBMs but falls below the threshold drug manufacturers are seeking. Medicare Part D plans following the model formulary would have to offer at least two drugs in each therapeutic category and pharmacologic class.